![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 12, 9641-9644, March 22, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Biochemistry, Chemistry, and the College of Medicine, University of Illinois, Urbana, Illinois 61801
Received for publication, December 19, 2001, and in revised form, January 15, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The kinetics of formation and breakdown of the
putative active oxygenating intermediate in cytochrome P450, a
ferryl-oxo-( P450 enzymes are ubiquitous in nature and carry out a wide range
of important reactions including the activation of carbon centers for
catabolism, steroid metabolism, and detoxification of xenobiotics (1).
Due to the important physiological functions of P450 enzymes, the
reaction intermediates of P450 chemistry have been a subject of
investigation for many years. Several discreet steps occur in the
hydroxylation chemistry of the cytochrome P450s including: substrate
binding, first electron transfer to the P450 from a physiological redox
partner, oxygen binding (to form oxy-P450), a second electron transfer
event (to form a reduced oxy or peroxo state), proton transfer to the
distal oxygen (forming hydroperoxo), and an oxygen scission event
producing a putative high valent iron-oxo species that subsequently
generates hydroxylated product (2). The high valent iron-oxo has long
been thought to be analogous to the activated iron species
characterized in other oxidative enzymes (horseradish peroxidase
(HRP),1 catalase, and
chloroperoxidase (CPO)) and referred to as Compound I, a
ferryl-oxo-( To probe the nature of Compound I, meta-chloroperoxybenzoic
acid (m-CPBA) has been used as an oxidizing agent to produce
this high valent iron-oxo through heterolytic cleavage of the organic peroxide in CPO and HRP. The Compound I species of CPO and HRP have
sufficient half-lives for resonance Raman and EPR studies and have been
well characterized (3, 5, 15-17). The same peroxy acid and its
derivatives have been used with P450s in attempts to generate
intermediates. Evidence for the existence of Compound I in P450s was
demonstrated through substrate oxygenation or hydroxylation in the
reaction of various organic peroxides with either liver microsomal P450
or CYP101, respectively (18, 19, 21).
Contrary to the evidence for Compound I formation in cytochrome P450
using m-CPBA, Blake and Coon (20) reported that the reactions of several peroxy acids with CYP2B4 generated other active
species, which are neither Compound I nor its one-electron-reduced adduct (Compound II). However, in previous studies the generation of
the Compound I intermediate in cytochrome P450 (CYP101) required a
large excess of peroxyacid, leading to the rapid formation, then
conversion of Compound I to other species. This inherent reactivity of
CYP101 from Pseudomonas putida has made the identification of Compound I tenuous, and, despite numerous efforts, kinetic analysis
could not be completed in the 10-ms time regime of the intermediate's
existence (21, 22).
To provide a characterization of the spectral properties of Compound I
in a thiolate-liganded heme protein, Harris et al. calculated the spectrum of methylmercaptooxyferryl
protoporphyrin IX using density functional theory (DFT) (23). The
calculated spectrum had a split Soret blue shifted from the ferric
Soret maximum by 60 nm with the Q bands appearing at 690 nm. Recently, Mössbauer and EPR spectroscopic studies of freeze-quenched
samples from the reaction of m-CPBA with CYP101 demonstrated
the existence of an organic radical and a ferryl species (24). The
techniques employed were not fast enough to capture the Compound I
intermediate on the path to the observed ferryl-radical species. Again,
the high concentration of m-CPBA used in these studies leads
to degradation of protein, which further complicates data analysis.
CYP119 is a thermostable P450 isolated from Sulfolobus
solfataricus with a melting temperature of 91 °C and remarkable
stability to pressure denaturation (25, 26). Thermostable enzymes are thought to have more rigid active site structures at room temperature than their mesophilic counterparts, which could lead to a slowing of
individual steps in the catalytic cycle (27). This alteration in
relative reaction rates may enable the resolution of intermediates that
occur too rapidly to be characterized in their mesophilic counterparts.
CYP119 has proven to be an effective model system for the study of the
intermediate states of the reaction cycle of this P450. For instance,
we recently employed cryoenzymology to define the hydroperoxo state
resulting from the one-electron reduction of the ferrous dioxygen state
(28). In this communication, we report the reaction kinetics of ferric
CYP119 with m-CPBA using stopped-flow spectroscopy and
document the formation of a spectral intermediate with the
characteristic spectrum of Compound I. The relevant time scales of
formation and breakdown of Compound I in this thermophilic P450 are
such that a kinetic characterization of these processes under various
conditions can be obtained for the first time.
m-CPBA was purchased from Aldrich-Sigma and
purified using the method described by Davies et al. (29).
Briefly, m-CPBA was re-crystallized in a 1:3 ether/petroleum
ether solution and characterized by NMR. Solutions of m-CPBA
for kinetic studies were prepared by addition of an acetone stock. The
m-CPBA concentrations were determined by iodide oxidation to
triiodide with the extinction coefficient of 25.5 mM Cytochrome P450 CYP119 expression and purification from
Escherichia coli are as published previously (26, 31).
Protein concentration was determined based on the Soret maximum at 415 nm ( Reaction kinetics of m-CPBA with ferric CYP119 were
first obtained by following the decay of the ferric signal at 415 nm
and a concurrent increase of absorption at 370 nm. Various
m-CPBA/CYP119 concentration ratios were investigated, as
shown in Fig. 1. At m-CPBA
concentrations less than half that of the ferric protein, the
absorption kinetics clearly show the formation of an intermediate by a
second order process. The spectral intermediate then decays in a first
order manner, with the spectrum returning to that of a ferric enzyme.
At 21 µM CYP119 and an m-CPBA concentration of 1.25, 2.5, and 5 µM, the maximal observed absorbance
change corresponds to 1, 2.1, and 3.4% of the total enzyme
concentration, respectively. At higher m-CPBA
concentrations, more complicated kinetic behavior was observed, with a
broadband decrease in absorbance indicating protein decomposition (see
"Discussion").
) porphyrin cation radical (Compound I), have been
analyzed in the reaction of a thermostable P450, CYP119, with
meta-chloroperoxybenzoic acid (m-CPBA). Upon
rapid mixing of m-CPBA with the ferric form of CYP119, an
intermediate with spectral features characteristic of a
ferryl-oxo-(
) porphyrin cation radical was clearly observed and
identified by the absorption maxima at 370, 610, and 690 nm. The rate
constant for the formation of Compound I was 3.20 (±0.3) × 105 M
1 s
1 at pH
7.0, 4 °C, and this rate decreased with increasing pH. Compound I of
CYP119 decomposed back to the ferric form with a first order rate
constant of 29.4 ± 3.4 s
1, which increased with
increasing pH. These findings form the first kinetic analysis of
Compound I formation and decay in the reaction of m-CPBA
with ferric P450.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) porphyrin cation radical (3-5). The intermediates in
the complex P450 reaction cycle have been gradually divulged through
the use of a wide range of spectroscopic techniques (6-8) and the use
of methods that allow access to the fast steps occurring after
O2 binding (2, 9). Recently the peroxo and hydroperoxo intermediates have been observed through the use of cryo-enzymology techniques combined with radiolysis, generating these intermediates through gradual temperature annealing (2, 10). Although there has been
no identification of a Compound I intermediate by these techniques, it
has been inferred by indirect measurements (2, 11, 12). The Compound I
state as well as the peroxo and hydroperoxo states of the enzyme have
been proposed to be active in oxygenation events (13, 14).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 cm
1 at 353 nm (30).
= 104 mM
1 cm
1).
All steady-state UV-visible spectra were recorded on a Hitachi U3300
spectrophotometer. Single wavelength stopped-flow measurements were
performed on a KinTek (Austin, TX) model SF-2001 stopped-flow system at
4 °C. For multiple-wavelength absorption studies, a stopped-flow
apparatus (model SX-18MV) and the associated computer system from
Applied Photophysics (Surrey, UK) were used. Multiple-wavelength absorption studies were carried out using a photodiode array detector and X-SCAN software (Applied Photophysics, Ltd.). The dead-time of this
instrument is about two milliseconds. In a typical experiment one
syringe contained CYP119 (6 µM heme) buffered in 100 mM phosphate (at various pH), and the other contained
various concentrations of m-CPBA. The reaction temperature
was controlled by a water bath. Spectral deconvolution and kinetic
analysis were performed by global analysis and numerical integration
methods using PRO-K software (Applied Photophysics, Ltd.).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (16K):
[in a new window]
Fig. 1.
Absorbance at 370 nm (A) and
415 nm (B) upon mixing ferric CYP119 with various
m-CPBA concentrations (pH 7.0) and 4 °C. The
final concentration of CYP119 after mixing was 21 µM, and
the m-CPBA concentrations are: 20 µM
(
), 10 µM (
), 5 µM
(
), 2.5 µM (
), and 1.25 µM
(
).
Fig. 2 shows intermediate formation by
the increase of absorption at 370 nm in the reaction of ferric CYP119
with a substoichiometric concentration of m-CPBA. The data
(
) are easily fit by a mechanism involving second order formation
and first order decay (solid line, Reaction 1). Moreover, to
assess the order of reactions (inset), the initial velocity
of the intermediate formation was plotted against m-CPBA
concentration, clearly showing the linear increase in velocity with
increasing substrate concentration, indicative of a second order
reaction. On the other hand, the decay rate constants obtained by the
mechanism described above are within the range of 27-33
s
1 and independent of m-CPBA concentration for
the reactions of 21 µM ferric CYP119 with 1.25, 2.5, and
5 µM m-CPBA. It is evident that the
decomposition of this intermediate goes through a first order process
under substoichiometric amount of m-CPBA. Note that at high
m-CPBA concentrations there appears to be a departure from
first order decomposition process, indicating a combination of protein
destruction and side oxidation processes. To better characterize the
first intermediate formed in this reaction, multi-wavelength kinetic
measurements were carried out at low m-CPBA
concentrations.
|
Rapid-scan stopped-flow spectrophotometry, together with singular value
decomposition, was used to provide spectral identification of the
observed intermediate. In this case, full spectra as a function of time
were analyzed using the following model.
|
|
|
The formation of Compound I at a ratio of m-CPBA to protein
of 1:2.5 (pH 7.0) had a second order rate (k1)
of 3.20 (± 0.3) × 105 M
1
s
1, and a first order decomposition rate
(k2) of 29.4 ± 3.4 s
1. When
m-CPBA concentrations were higher than the concentration of
CYP119, protein decay occurred in multiple complicated kinetic processes.
To probe the role of proton concentration on Compound I formation, the reaction between CYP119 and m-CPBA was studied as a function of pH by means of multi-wavelength measurements. The rates of formation and decay for compound I in CYP119 at different pH are shown in Table I. Additionally, the rates of formation and decay for Compound I were increased with an increase in reaction temperature. The Arrhenius plot (data not shown) for the Compound I formation reaction (k1) equates to an Ea = 14.1 kcal/mole and the decay rate (k2) Ea = 18.1 kcal/mol.
|
| |
DISCUSSION |
|---|
|
|
|---|
The thermostable cytochrome P450 CYP119 has proven to be an excellent system for investigating the nature of intermediates with higher oxidation states of this important class of heme proteins. Previous attempts to form and isolate a Compound I intermediate in CYP101 and other P450s were hampered by the use of a large excess of peroxyacids, leading to rapid progression from Compound I to other intermediates and concomitant protein destruction (21, 24). The formation of Compound I in CYP119 was slowed both by the use of lower concentrations of m-CPBA and by the temperature at which the experiments were carried out (4 °C), which was well below the physiological temperature for this thermophilic enzyme (80 °C). This allowed the detection of an intermediate clearly defined as Compound I well within the time scale accessible by stopped-flow spectroscopy. Protein degradation, which can often complicate kinetic analysis, was largely avoided. These properties of Compound I formation in CYP119 have made the spectral and kinetic characterization of this previously elusive chemical species in P450s possible.
CYP119 is capable of forming an intermediate with the spectral
characteristics of a Compound I, ferryl-oxo-(
) porphyrin cation radical, when rapidly mixed with the peroxy acid m-CPBA. The
spectral similarities of the CYP119 Compound I to the optical spectra
of Compound I in other heme proteins are summarized in Table
II. The Soret band of this Compound I was
asymmetric and single-peaked at 370 nm (Fig. 3A), while
asymmetric Soret bands of both CYP101 and CPO are at 367 nm (21, 32).
This asymmetric feature has been deconvoluted using Gaussian-type
transition bands and assigned as the splitting Soret band of the
d-type hyper-porphyrin in the recent spectroscopic studies
of CPO Compound I (16). Moreover, the visible spectrum of CYP119
Compound I has almost identical absorption intensity at 610 and 690 nm,
whereas the intensity at 610 nm of CPO Compound I is lower than its
absorption at 688 nm. Overall, these findings indicate the similarity
between the Compound I entity of these two thiolate-ligated heme
proteins and the minor differences in the absorption spectra can be
attributed to their electronic structure differences. Similar spectral
characteristics of P450 Compound I have also been generated from DFT
calculations by Harris et al. (23). The calculated spectra
of the methylmercaptooxyferryl protoporphyrin IX model structure
are blue-shifted by 50-60 nm in both the ferric resting state and
Compound I; however, the other features and the peak shapes are quite
similar to the results presented here. The major peak in the split
Soret band of the calculated Compound I spectrum is blue-shifted from
the ferric Soret by 60 nm, similar to the 45 nm shift in the CYP119
Compound I. Additionally, the Q-bands of the calculated Compound I are shifted to 690 nm, with the equivalent bands in the same location for
CYP119 Compound I.
|
The reaction of CYP101 with m-CPBA was shown by Egawa et al. (21) to form an intermediate with spectral characteristics similar to those of CYP119 Compound I. However, this intermediate was formed in the dead-time of the stopped-flow instrument used and decomposed rapidly into a series of unidentified intermediates. The high concentration of peracid used also caused breakdown of the protein. The experimental conditions necessary to generate the putative Compound I in CYP101 included the use of a 30-fold excess of m-CPBA, increasing the formation rate to the point that the intermediate was fleetingly formed and rapidly decayed. The Compound I, formed under the conditions presented here, in CYP119 has a half-life more than an order of magnitude longer than the apparent CYP101 half-life with high concentrations of m-CPBA. This longer half-life has allowed the first kinetic characterization of the formation and decomposition processes for Compound I in a P450. To compare the reaction kinetics of CYP119 Compound I with other heme proteins, rate constants for Compound I formation and decay in various systems are summarized in Table III. While the Compound I states of the other three proteins are stable enough to detect at room temperature, characterization of a P450 Compound I species necessitated the utilization of a thermophilic protein and low temperature (4 °C).
|
The kinetic competence in the conversion of the observed intermediate to an oxygenated product would be a valuable piece of information. Unfortunately, the physiological substrate for this enzyme is not known. However, the addition of laurate to the reaction mixture in a double mixing configuration after the addition of m-CPBA leads to complete quenching of the observed spectral intermediate within the dead-time of the instrument. The reaction of a Compound I intermediate with juxtaposed substrate has been suggested to be very fast, and hence we do not expect to directly observe the kinetic conversion to product. Analysis of the reaction mixture following addition of laurate in this double-mix experiment demonstrated the presence of hydroxylaurate as a product (data not shown), suggesting the coupling of intermediate decay to substrate oxygenation.
The pH dependence for Compound I formation reflects the pK of m-CPBA of 7.4. Previous data have shown that the protonated form of m-CPBA is the active species for Compound I formation, leading to increased rates of Compound I formation at lower pH (20). The pH dependence of the m-CPBA reaction with CYP119 is similar to the behavior of catalase reacting with peroxyacetic acid (33). In both cases the results are most simply interpreted as a reaction between the enzyme and non-ionized peroxy acid molecules. This is substantiated by similar pH dependence for the reaction between peroxybenzoic acid and horseradish peroxidase (29). Additionally, the Ea for Compound I formation (14.1 kcal/mol) in CYP119 is relatively high compared with the reaction of hydrogen peroxide with peroxidases (2.5-5 kcal/mol) that utilize hydrogen peroxide as a substrate (34). This is in agreement with the recent findings for the reaction of prostaglandin endoperoxide synthase with hydrogen peroxide, which also has an elevated Ea (~24 kcal/mol) of its Compound I formation and does not use hydrogen peroxide as a native substrate (35).
The disappearance of CYP119 Compound I is a first order process. This makes it unlikely that the degradation of Compound I involves O2 formation by nucleophilic attack of a second m-CPBA molecule as observed in chloroperoxidase (32). Similarly, the possibility of the formation of Compound II from the reaction of Compound I with a second peroxy acid molecule as in HRP can be ruled out. One possibility is that the oxene oxygen is transferred to the protein. Alternatively, it has been suggested that the slow regeneration of the ferric state in catalase, from Compound I, is carried out by a reducing equivalent originating from the protein matrix (33, 36). The CYP119 Compound I decays to the low-spin ferric form at a rate about 105 times faster than that of catalase Compound I. These active species can be reduced by any adventitious reducing equivalent from the protein matrix (4). The pH dependence of the Compound I decomposition rate is similar to the decay of ferryl intermediate in cytochrome c oxidase, which was explained by an auto-reduction pathway (37). Taken together, the mechanism of degradation of CYP119 Compound I and the regeneration of the ferric enzyme can only be determined with more experimental analysis.
The kinetic characterization of Compound I formation in CYP119 has
allowed for the optimization of conditions for the maximal production
of this putative reaction intermediate in time regimes accessible to
other spectroscopic methods. The information thus obtained will aid in
the further determination of the nature of Compound I in P450 reactions.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Prof. Robert Gennis and Dr. Joel Morgan for the use of their Applied Photophysics rapid scanning stopped-flow spectrophotometer.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants GM 31756 and GM 33775.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: School of Molecular
and Cellular Biology, 505 S. Goodwin Ave., University of Illinois at
Champaign-Urbana, Urbana, IL 61801. Tel.: 217-244-7395; Fax: 217-265-4073; E-mail: s-sligar@uiuc.edu.
Published, JBC Papers in Press, January 17, 2002, DOI 10.1074/jbc.C100745200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HRP, horseradish peroxidase; CPO, chloroperoxidase; m-CPBA, meta-chloroperoxybenzoic acid; DFT, density functional theory.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Guengerich, F. P.
(2001)
Chem. Res. Toxicol.
14,
611-650[Medline]
[Order article via Infotrieve] |
| 2. |
Davydov, R.,
Makris, T. M.,
Kofman, V.,
Werst, D. E.,
Sligar, S. G.,
and Hoffman, B. M.
(2001)
J. Am. Chem. Soc.
123,
1404-1415 |
| 3. |
Palaniappan, V.,
and Terner, J.
(1989)
J. Biol. Chem.
264,
16046-16053 |
| 4. |
Benecky, M. J.,
Frew, J. E.,
Scowen, N.,
Jones, P.,
and Hoffman, B. M.
(1993)
Biochemistry
32,
11929-11933[CrossRef][Medline]
[Order article via Infotrieve] |
| 5. |
Hosten, C. M.,
Sullivan, A. M.,
Palaniappan, V.,
Fitzgerald, M. M.,
and Terner, J.
(1994)
J. Biol. Chem.
269,
13966-13978 |
| 6. |
Lipscomb, J. D.
(1980)
Biochemistry
19,
3590-3599[CrossRef][Medline]
[Order article via Infotrieve] |
| 7. |
Yu, C. A.,
Gunsalus, I. C.,
Katagiri, M.,
Suhara, K.,
and Takemori, S.
(1974)
J. Biol. Chem.
249,
94-101 |
| 8. |
Bangcharoenpaurpong, O.,
Rizos, A. K.,
Champion, P. M.,
Jollie, D.,
and Sligar, S. G.
(1986)
J. Biol. Chem.
261,
8089-8092 |
| 9. |
Denisov, I. G.,
Makris, T. M.,
and Sligar, S. G.
(2001)
J. Biol. Chem.
276,
11648-11652 |
| 10. |
Davydov, R.,
Macdonald, I. D. G.,
Makris, T. M.,
Sligar, S. G.,
and Hoffman, B. M.
(1999)
J. Am. Chem. Soc.
121,
10654-10655[CrossRef] |
| 11. |
Aikens, J.,
and Sligar, S. G.
(1994)
J. Am. Chem. Soc.
116,
1143-1144[CrossRef] |
| 12. |
Schlichting, I.,
Berendzen, J.,
Chu, K.,
Stock, A. M.,
Maves, S. A.,
Benson, D. E.,
Sweet, R. M.,
Ringe, D.,
Petsko, G. A.,
and Sligar, S. G.
(2000)
Science
287,
1615-1622 |
| 13. |
Raner, G. M.,
Hatchell, A. J.,
Morton, P. E.,
Ballou, D. P.,
and Coon, M. J.
(2000)
J. Inorg. Biochem.
81,
153-160[CrossRef][Medline]
[Order article via Infotrieve] |
| 14. |
Vaz, A. D. N.,
Kessell, K. J.,
and Coon, M. J.
(1994)
Biochemistry
33,
13651-13661[CrossRef][Medline]
[Order article via Infotrieve] |
| 15. |
Egawa, T.,
Miki, H.,
Ogura, T.,
Makino, R.,
Ishimura, Y.,
and Kitagawa, T.
(1992)
FEBS Lett.
305,
206-208[CrossRef][Medline]
[Order article via Infotrieve] |
| 16. |
Egawa, T.,
Proshlyakov, D. A.,
Miki, H.,
Makino, R.,
Ogura, T.,
Kitagawa, T.,
and Ishimura, Y.
(2001)
J. Biol. Inorg. Chem.
6,
46-54[CrossRef][Medline]
[Order article via Infotrieve] |
| 17. |
Kincaid, J. R.,
Zheng, Y., Al-,
Mustafa, J.,
and Czarnecki, K.
(1996)
J. Biol. Chem.
271,
28805-28811 |
| 18. |
Guengerich, F. P.,
Vaz, A. D. N.,
Raner, G. N.,
Pernecky, S. J.,
and Coon, M. J.
(1997)
Mol. Pharmacol.
51,
147-151 |
| 19. | Sligar, S. G., Shastry, B. S., and Gunsalus, I. C. (1976) in Microsomes and Drug Oxidations (Ullrich, V. , Roots, I. , Hildebrandt, A. , Estabrook, R. W. , and Conney, A. H., eds) , pp. 204-205, Pergamon Press, Oxford |
| 20. |
Blake, R. C. I.,
and Coon, M. J.
(1989)
J. Biol. Chem.
264,
3694-3701 |
| 21. |
Egawa, T.,
Shimada, H.,
and Ishimura, Y.
(1994)
Biochem. Biophys. Res. Commun.
201,
1464-1469[CrossRef][Medline]
[Order article via Infotrieve] |
| 22. |
Wagner, G. C.,
Palcic, M. M.,
and Dunford, H. B.
(1983)
FEBS Lett.
156,
244-248[Medline]
[Order article via Infotrieve] |
| 23. |
Harris, D.,
Loew, G.,
and Waskell, L.
(2001)
J. Inorg. Biochem.
83,
309-318[Medline]
[Order article via Infotrieve] |
| 24. |
Schünemann, V.,
Jung, C.,
Trautwein, A. X.,
Mandon, D.,
and Weiss, R.
(2000)
FEBS Lett.
479,
149-154[CrossRef][Medline]
[Order article via Infotrieve] |
| 25. |
Tschirret-Guth, R. A.,
Koo, L. S.,
Hui Bon Hoa, G.,
and Ortiz de Montellano, P. R.
(2001)
J. Am. Chem. Soc.
123,
3412-3417[Medline]
[Order article via Infotrieve] |
| 26. |
McLean, M. A.,
Maves, S. A.,
Weiss, K. E.,
Krepich, S.,
and Sligar, S. G.
(1998)
Biochem. Biophys. Res. Commun.
252,
166-172[CrossRef][Medline]
[Order article via Infotrieve] |
| 27. |
Michels, P. C.,
Clark,
and Douglas, S.
(1997)
Appl. Environ. Microbiol.
63,
3985-3991[Abstract] |
| 28. |
Denisov, I. G.,
Hung, S. C.,
Weiss, K. E.,
McLean, M. A.,
Shiro, Y.,
Park, S. Y.,
Champion, P. M.,
and Sligar, S. G.
(2001)
J. Inorg. Biochem.
87,
215-226[CrossRef][Medline]
[Order article via Infotrieve] |
| 29. |
Davies, D. M.,
Jones, P.,
and Mantle, D.
(1976)
Biochem. J.
157,
247-253[Medline]
[Order article via Infotrieve] |
| 30. |
Ramette, R. W.,
and Sandford, R. W.
(1965)
J. Am. Chem. Soc.
87,
5001-5005[CrossRef] |
| 31. |
Maves, S. A.,
and Sligar, S. G.
(2001)
Protein Sci.
10,
161-168 |
| 32. |
Hager, L. P.,
Doubek, D. L.,
Silverstein, R. M.,
Hargis, J. H.,
and Martin, J. C.
(1972)
J. Am. Chem. Soc.
94,
4364-4366[Medline]
[Order article via Infotrieve] |
| 33. |
Jones, P.,
and Middlemiss, D. N.
(1972)
Biochem. J.
130,
411-415[Medline]
[Order article via Infotrieve] |
| 34. |
Marklund, S.,
Ohlsson, P. I.,
Opara, A.,
and Paul, K. G.
(1974)
Biochim. Biophys. Acta
350,
304-313[Medline]
[Order article via Infotrieve] |
| 35. |
Bakovic, M.,
and Dunford, H. B.
(1996)
Biochem. Cell Biol.
74,
117-124[Medline]
[Order article via Infotrieve] |
| 36. |
Pfister, T. D.,
Gengenbach, A. J.,
Syn, S.,
and Lu, Y.
(2001)
Biochemistry
40,
14942-14951[Medline]
[Order article via Infotrieve] |
| 37. |
Fabian, M.,
and Palmer, G.
(2001)
Biochemistry
40,
1867-1874[CrossRef][Medline]
[Order article via Infotrieve] |
| 38. |
Araiso, T.,
Rutter, R.,
Palcic, M. M.,
Hager, L. P.,
and Dunford, H. B.
(1981)
Can. J. Biochem.
59,
233-236[Medline]
[Order article via Infotrieve] |
| 39. |
Rodriguez-Lopez, J. N.,
Hernández-Ruiz, J.,
Garcia-Cánovas, F.,
Thorneley, R. N. F.,
Acosta, N.,
and Arnao, M. B.
(1997)
J. Biol. Chem.
272,
5469-5476 |
This article has been cited by other articles:
![]() |
M. Newcomb, J. A. Halgrimson, J. H. Horner, E. C. Wasinger, L. X. Chen, and S. G. Sligar Reactive Oxygen Species Special Feature: X-ray absorption spectroscopic characterization of a cytochrome P450 compound II derivative PNAS, June 17, 2008; 105(24): 8179 - 8184. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sudhamsu and B. R. Crane Structure and Reactivity of a Thermostable Prokaryotic Nitric-oxide Synthase That Forms a Long-lived Oxy-Heme Complex J. Biol. Chem., April 7, 2006; 281(14): 9623 - 9632. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Glascock, D. P. Ballou, and J. H. Dawson Direct Observation of a Novel Perturbed Oxyferrous Catalytic Intermediate during Reduced Putidaredoxin-initiated Turnover of Cytochrome P-450-CAM: PROBING THE EFFECTOR ROLE OF PUTIDAREDOXIN IN CATALYSIS J. Biol. Chem., December 23, 2005; 280(51): 42134 - 42141. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Stone, R. K. Behan, and M. T. Green X-ray absorption spectroscopy of chloroperoxidase compound I: Insight into the reactive intermediate of P450 chemistry PNAS, November 15, 2005; 102(46): 16563 - 16565. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Spolitak, J. H. Dawson, and D. P. Ballou Reaction of Ferric Cytochrome P450cam with Peracids: KINETIC CHARACTERIZATION OF INTERMEDIATES ON THE REACTION PATHWAY J. Biol. Chem., May 27, 2005; 280(21): 20300 - 20309. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yun, K.-H. Kim, M. W. Calcutt, and F. P. Guengerich Kinetic Analysis of Oxidation of Coumarins by Human Cytochrome P450 2A6 J. Biol. Chem., April 1, 2005; 280(13): 12279 - 12291. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Schunemann, F. Lendzian, C. Jung, J. Contzen, A.-L. Barra, S. G. Sligar, and A. X. Trautwein Tyrosine Radical Formation in the Reaction of Wild Type and Mutant Cytochrome P450cam with Peroxy Acids: A MULTIFREQUENCY EPR STUDY OF INTERMEDIATES ON THE MILLISECOND TIME SCALE J. Biol. Chem., March 19, 2004; 279(12): 10919 - 10930. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Groves Bioinorganic Chemistry Special Feature: The bioinorganic chemistry of iron in oxygenases and supramolecular assemblies PNAS, April 1, 2003; 100(7): 3569 - 3574. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Lim, J.-U. Rohde, A. Stubna, M. R. Bukowski, M. Costas, R. Y. N. Ho, E. Munck, W. Nam, and L. Que Jr. Bioinorganic Chemistry Special Feature: An FeIV==O complex of a tetradentate tripodal nonheme ligand PNAS, April 1, 2003; 100(7): 3665 - 3670. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-U. Rohde, J.-H. In, M. H. Lim, W. W. Brennessel, M. R. Bukowski, A. Stubna, E. Munck, W. Nam, and L. Que Jr. Crystallographic and Spectroscopic Characterization of a Nonheme Fe(IV)&cjs0811;O Complex Science, February 14, 2003; 299(5609): 1037 - 1039. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |